Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport

Katsuo Amioka, Takafumi Kuzuya, Hideyuki Kushihara, Masayuki Ejiri, Atsumi Nitta, Toshitaka Nabeshima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Carvedilol is often used to treat hypertension and for prophylaxis in vascular sclerosis in renal transplant recipients, who require concomitant treatment with ciclosporin. However, there are few reports regarding the pharmacokinetic interactions between carvedilol and ciclosporin. We have investigated the potential effects of carvedilol on the pharmacokinetics of ciclosporin, and examined the inhibitory effects of carvedilol on P-glycoprotein-mediated transcellular transport using Caco2 cells. Ciclosporin alone or with carvedilol was orally or intravenously administered to rats. The oral administration of carvedilol (10 mg kg-1) with Ciclosporin (10 mg kg-1) increased the whole blood concentration of ciclosporin. When Ciclosporin (3 mg kg-1) was intravenously administered with carvedilol (3 mg kg-1), there was no difference in the whole blood ciclosporin concentration between administration with and without carvedilol. Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%. In Caco2 cells, carvedilol caused a concentration-dependent increase in the intracellular accumulation of ciclosporin, and its effect was comparable with that of verapamil. Carvedilol considerably raised the concentration of ciclosporin in the blood and this interaction was associated with the absorption phase of ciclosporin. This interaction was caused by the inhibition of P-glycoprotein-mediated transport by carvedilol in the intestine.

Original languageEnglish
Pages (from-to)1383-1387
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume59
Issue number10
DOIs
Publication statusPublished - 01-10-2007
Externally publishedYes

Fingerprint

P-Glycoprotein
Cyclosporine
Biological Availability
carvedilol
Pharmacokinetics
Transcytosis
Arteriosclerosis
Verapamil
Intestines
Oral Administration
Hypertension
Kidney

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Amioka, Katsuo ; Kuzuya, Takafumi ; Kushihara, Hideyuki ; Ejiri, Masayuki ; Nitta, Atsumi ; Nabeshima, Toshitaka. / Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. In: Journal of Pharmacy and Pharmacology. 2007 ; Vol. 59, No. 10. pp. 1383-1387.
@article{d30ec5a4b67d4d60a1bb79022d1564fd,
title = "Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport",
abstract = "Carvedilol is often used to treat hypertension and for prophylaxis in vascular sclerosis in renal transplant recipients, who require concomitant treatment with ciclosporin. However, there are few reports regarding the pharmacokinetic interactions between carvedilol and ciclosporin. We have investigated the potential effects of carvedilol on the pharmacokinetics of ciclosporin, and examined the inhibitory effects of carvedilol on P-glycoprotein-mediated transcellular transport using Caco2 cells. Ciclosporin alone or with carvedilol was orally or intravenously administered to rats. The oral administration of carvedilol (10 mg kg-1) with Ciclosporin (10 mg kg-1) increased the whole blood concentration of ciclosporin. When Ciclosporin (3 mg kg-1) was intravenously administered with carvedilol (3 mg kg-1), there was no difference in the whole blood ciclosporin concentration between administration with and without carvedilol. Co-administration with carvedilol increased ciclosporin bioavailability from 33{\%} to 70{\%}. In Caco2 cells, carvedilol caused a concentration-dependent increase in the intracellular accumulation of ciclosporin, and its effect was comparable with that of verapamil. Carvedilol considerably raised the concentration of ciclosporin in the blood and this interaction was associated with the absorption phase of ciclosporin. This interaction was caused by the inhibition of P-glycoprotein-mediated transport by carvedilol in the intestine.",
author = "Katsuo Amioka and Takafumi Kuzuya and Hideyuki Kushihara and Masayuki Ejiri and Atsumi Nitta and Toshitaka Nabeshima",
year = "2007",
month = "10",
day = "1",
doi = "10.1211/jpp.59.10.0008",
language = "English",
volume = "59",
pages = "1383--1387",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "10",

}

Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. / Amioka, Katsuo; Kuzuya, Takafumi; Kushihara, Hideyuki; Ejiri, Masayuki; Nitta, Atsumi; Nabeshima, Toshitaka.

In: Journal of Pharmacy and Pharmacology, Vol. 59, No. 10, 01.10.2007, p. 1383-1387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport

AU - Amioka, Katsuo

AU - Kuzuya, Takafumi

AU - Kushihara, Hideyuki

AU - Ejiri, Masayuki

AU - Nitta, Atsumi

AU - Nabeshima, Toshitaka

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Carvedilol is often used to treat hypertension and for prophylaxis in vascular sclerosis in renal transplant recipients, who require concomitant treatment with ciclosporin. However, there are few reports regarding the pharmacokinetic interactions between carvedilol and ciclosporin. We have investigated the potential effects of carvedilol on the pharmacokinetics of ciclosporin, and examined the inhibitory effects of carvedilol on P-glycoprotein-mediated transcellular transport using Caco2 cells. Ciclosporin alone or with carvedilol was orally or intravenously administered to rats. The oral administration of carvedilol (10 mg kg-1) with Ciclosporin (10 mg kg-1) increased the whole blood concentration of ciclosporin. When Ciclosporin (3 mg kg-1) was intravenously administered with carvedilol (3 mg kg-1), there was no difference in the whole blood ciclosporin concentration between administration with and without carvedilol. Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%. In Caco2 cells, carvedilol caused a concentration-dependent increase in the intracellular accumulation of ciclosporin, and its effect was comparable with that of verapamil. Carvedilol considerably raised the concentration of ciclosporin in the blood and this interaction was associated with the absorption phase of ciclosporin. This interaction was caused by the inhibition of P-glycoprotein-mediated transport by carvedilol in the intestine.

AB - Carvedilol is often used to treat hypertension and for prophylaxis in vascular sclerosis in renal transplant recipients, who require concomitant treatment with ciclosporin. However, there are few reports regarding the pharmacokinetic interactions between carvedilol and ciclosporin. We have investigated the potential effects of carvedilol on the pharmacokinetics of ciclosporin, and examined the inhibitory effects of carvedilol on P-glycoprotein-mediated transcellular transport using Caco2 cells. Ciclosporin alone or with carvedilol was orally or intravenously administered to rats. The oral administration of carvedilol (10 mg kg-1) with Ciclosporin (10 mg kg-1) increased the whole blood concentration of ciclosporin. When Ciclosporin (3 mg kg-1) was intravenously administered with carvedilol (3 mg kg-1), there was no difference in the whole blood ciclosporin concentration between administration with and without carvedilol. Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%. In Caco2 cells, carvedilol caused a concentration-dependent increase in the intracellular accumulation of ciclosporin, and its effect was comparable with that of verapamil. Carvedilol considerably raised the concentration of ciclosporin in the blood and this interaction was associated with the absorption phase of ciclosporin. This interaction was caused by the inhibition of P-glycoprotein-mediated transport by carvedilol in the intestine.

UR - http://www.scopus.com/inward/record.url?scp=35348930627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348930627&partnerID=8YFLogxK

U2 - 10.1211/jpp.59.10.0008

DO - 10.1211/jpp.59.10.0008

M3 - Article

C2 - 17910813

AN - SCOPUS:35348930627

VL - 59

SP - 1383

EP - 1387

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 10

ER -